
TD Cowen keeps Buy on Gilead as HIV and oncology drive strong growth outlook
TD Cowen reaffirmed its Buy rating on Gilead Sciences, highlighting the company's strong growth driven by HIV and oncology treatments. Gilead reported its best growth in over a decade in Q3 2026 and is expanding into inflammation treatments. The comp...





